Navigation Links
Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Study results show that elevated lipoprotein-associated phospholipase A2 (Lp-PLA2), a cardiovascular-specific inflammatory enzyme associated with unstable plaque that can lead to heart attack and stroke, is especially predictive of heart disease risk in patients with the metabolic syndrome--a serious medical condition that affects nearly 50 million Americans. The results, which were presented yesterday at the American College of Cardiology's annual scientific session, confirm previous findings demonstrating the association between elevated Lp-PLA2 and coronary heart disease.

Investigators at the University of Utah in Salt Lake City used the PLAC test from diaDexus to measure Lp-PLA2 levels in blood samples from almost 1,500 patients enrolled in the Intermountain Heart Collaborative Study. The patients also underwent coronary angiography to determine the presence of heart disease and were tracked for up to 10 years. Results showed that Lp-PLA2 was a clinically important predictor of heart disease and future death in patients with the metabolic syndrome, a dangerous precursor to diabetes characterized by high blood pressure, high triglycerides, high fasting blood glucose, low high-density lipoprotein, and small, dense low-density lipoprotein. Lp-PLA2 also predicted heart disease death risk in non-metabolic syndrome patients.

According to Richard Lanman, M.D., diaDexus' chief medical officer, the findings are important because of the large number of patients with the metabolic syndrome who may be at significantly increased risk for diabetes, stroke, and heart disease. "Interest in the metabolic syndrome has been increasing along with Americans' growing waistlines," Lanman said. "This study confirms earlier results indicating that elevated Lp-PLA2 is independent from and additive to the increased cardiovascular risk associated with insulin resistance. The addition al information about rupture-prone plaque provided by Lp-PLA2 can help identify which metabolic syndrome patients should be targeted with more aggressive treatment."

A second study presented at the meeting focused on treatment of 55 metabolic syndrome patients with elevated levels of Lp-PLA2 and triglycerides. The results presented by Dr. Robert Rosenson of the University of Michigan showed that three months of treatment with fenofibrate (160 mg/day) reduced Lp-PLA2 levels measured with the PLAC test. Lanman said these findings highlight the opportunity for plaque stabilization with lipid-modifying medication when patients with the metabolic syndrome also have elevated Lp-PLA2. "The PLAC test identifies patients who benefit from lipid-modifying therapy such as fenofibrate to help prevent cardiovascular events," he said.

diaDexus, Inc., a privately held biotechnology company based in South San Francisco, Calif., is focused on the discovery, development, and commercialization of innovative, patent-protected diagnostic products with high clinical value. The PLAC test is a simple blood test that has been cleared for marketing by the Food and Drug Administration as an aid in predicting risk for coronary heart disease and ischemic stroke associated with atherosclerosis. In addition to the PLAC test, diaDexus is developing a pipeline of novel cancer diagnostic tests. For information, visit www.plactest.com or www.diaDexus.com.

Note to editors: The American College of Cardiology's 56th annual scientific session is being held at the Ernest N. Morial Convention Center in New Orleans, March 24-27, 2007. diaDexus' booth number is 1232. For copies of the abstracts, please contact Barbara Sullivan at 714/374-6174.

Contact

Sullivan & Associates
Barbara Sullivan, 714-374-6174
bsullivan@sullivanpr.com
or
diaDexus, Inc.
Christina Andrian, 650-246-6476 candrian@diadexus.com


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... LONDON , May 24, 2016 ... erfüllt beide primären Endpunkte ... und Überlegenheit in ‚ausgezeichneter plus guter ... aufsteigenden Colons    ,      (Logo: ... B.V. gab heute neue positive Daten von der ...
(Date:5/24/2016)... Mass. , May 24, 2016  NxStage Medical, ... technology company focused on advancing renal care, today announced ... plans to participate in the following schedule of investor ... be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, June ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 /PRNewswire/ ... primer stent de doble terapia del mundo, introduce ... fístula arteriovenosa. OrbusNeich, una compañía global ... cambian las vidas, ha expandido su cartera incluyendo ... catéteres balón JADE™ y Scoreflex™ PTA son los ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Each year ... complementary medicine. Allison Outerbridge is this year’s Life University winner of ... at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching her last ...
(Date:5/26/2016)... ... 26, 2016 , ... W.S. Badger Co. Inc ., the maker of ... When Work Works Award for its use of effective workplace strategies to increase business ... project administered by the Families and Work Institute (FWI) and the Society for Human ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, ... as a partner for the Tamika Catchings Legacy Tour that will commemorate ... leader in hardwood basketball surfaces in all forms and levels of the game, Connor ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million ... million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world will ... Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration of ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found ... The 550 employees of Sun Health Senior Living (SHSL) may not share ... their doctor and prescription copays for the year, while holding the line on increasing ...
Breaking Medicine News(10 mins):